Borough Park
1428 36th Street
Suite 107
Brooklyn, NY 11218
Manhaceat

Crown Heights
555 Lefferts Avenue
Brooklyn, NY 11225

 Manhasset
 Rockville Centre
 Elmsford/Terrytown

 333 East Shore Road
 165 North Village Avenue
 555 Taxter Road

 Suite 201
 Suite 133
 3rd Floor

 Manhasset, NY 11030
 Rockville Centre, NY 11570
 Elmsford, NY 10523

Manhattan
57W 57Street
Suite 601
New York, NY 10019





Manhattan		
225 E 70th Street		
Suite 1E		
New York, NY 1002		
New York, NY 1002		

Long Beach
917 Beech Street
Long Beach, NY 11561

Holbrook/ Ronkonkoma
233 Union Ave
Suite 207
Holbrook, NY 11741 Scarsdale

495 Central Park Avenue
Suite 205
Scarsdale NV 10583

Queens 64-05 Yellowstone Blvd CF104 Forest Hills, NY 11375

Manhattan	
225 East 70th Street	
New York, NY 10021	

5 Towns
141 Washington Avenue
Cedarhurst, NY 11559

Provider _____

Provider Ora	lar Form

Ublituximab-xiiy (Briumvi) Provider Order Form Date:				
PATIENT INFORMATION				
Name:	DOB: SEX: M F			
ICD-10 code (required):	ICD-10 description:			
□NKDA Allergies:	Weight lbs/kg:			
REFERRA	REFERRAL STATUS			
□New Referral □Referral Renewal □Medication/Order Change □Benefits Verification Only □Discontinuation Order				
PHYSICIAN INFORMATION				
Referral Coordinator Name:	Referral Coordinator Email:			
Ordering Provider:	Provider NPI:			
Referring Practice Name:	Phone: Fax:			
Practice Address:	City: State: Zip Code:			
MURSING ☐ Hepatitis B status & date (list results here & attach clinicals) ☐ Provide nursing care per ThrlVewell Procedures, including reaction management and post-procedure observation Based on the manufacturer PI, most payors require a quantitative serum immunoglobulin screening prior to Briumvi induction. ☐ Ihave attached results from a recent quantitative serum immunoglobulin test (list results here & attach clinicals): ☐ linstruct ThrlVewell to draw quantitative serum immunoglobulin prior to first induction infusion (if required by payor). LABORATORY ORDERS ☐ CBC ☐ at each dose ☐ every ☐ CMP ☐ at each dose ☐ every ☐ CRP ☐ at each dose ☐ every ☐ Other: ☐ Dose: ☐ Route ☐ Frequency: ☐ PRE-MEDICATION ORDERS The following are manufacturer recommended premedication regimens: ☐ acetaminophen (Tylenol) ☐ 500mg / ☐ 650mg / ☐ 1000mg PO ☐ methylprednisolone (Solu-Medrol) ☐ 40mg / ☐ 125mg IV ☐ diphenhydramine (Benadryl) ☐ 25mg / ☐ 50mg ☐ PO / IV ADDITIONAL PRE-MEDICATION ORDERS ☐ cetirizine (Zyrtec) 10mg PO ☐ loratadine (Claritin) 10mg PO ☐ loratadine (Claritin) 10mg PO ☐ Other: ☐ Dose: ☐ Route: ☐ Frequency: ☐ Route: ☐ Frequency: ☐ Frequency: ☐ Route: ☐ Frequency:	THERAPY ADMINISTRATION ✓ Ublituximab-xiiy (Briumvi) intravenous infusion □ Induction: Dose: 150mg in 250ml 0.9% NS over four hours followed by 450mg in 250ml 0.9% NS over one hour two weeks later. After induction, continue with the maintenance dosing and schedule below. □ Maintenance: Dose: 450mg in 250ml 0.9%NS over one hour 24 weeks after the first infusion and every 24 weeks thereafter. ☑ Flush with 0.9% NS at the completion of infusion of first two infusions. If no infusion reaction or hypersensitivity has been observed, patient is not required to stay for subsequent infusions. □ Refills: □ Zero / □ for 12 months / □ (if not indicated order will expire one year from date signed) SPECIAL INSTRUCTIONS			
ORDERING PROVIDER Signature X	Date			
organica / L				

Phone _____ Fax ____